PATENT CLAIM ANALYSIS

Application Number: 15894546
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["435", "006100"]

Abstract:
The invention relates to improved methods, devices, and kits for identifying and implementing an appropriate treatment regimen for subjects suffering from hypertension.

Claim (Index 67):
A method for treating cardiovascular hypertension in a patient comprising administering to the patient as a first line therapy a first line drug selected from a diuretic, a vasodilator, a beta blocker or an ACE inhibitor wherein the selection and administration of the first line drug is made by obtaining sample of fluid or tissue from the patient, obtaining polypeptide sequence and/or DNA sequence analyses of the sample relating to the following nineteen peptide and/or DNA sequences:\n 1. an ADRB1 (\u03b2 1 AR) polypeptide with serine at about position 49; 2. an ADRB1 nucleic acid with rs1801252 (SEQ ID NO:2), wherein the rs1801252 variable nucleotide is adenine; 3. an ADRB1 (\u03b2 1 AR) polypeptide with arginine at about position 389; 4. an ADRB1 nucleic acid with rs1801253 (SEQ ID NO:3), wherein the rs1801253 variable nucleotide is cytosine; 5. an ADRB2 (\u03b2 2 AR) polypeptide with glycine at about position 16; 6. an ADRB2 nucleic acid with rs1042713 (SEQ ID NO:6), wherein the rs1042713 variable nucleotide is guanine; 7. an ADRB2 (\u03b2 2 AR) polypeptide with glutamic acid at about position 27; and/or 8. an ADRB2 nucleic acid with rs1042714 (SEQ ID NO:7), wherein the rs1042714 variable nucleotide is guanine; 9. CYP2D6 polypeptide or a CYP2D6 nucleic acid with a CYP2D6-defective mutation; 10. homozygous for a CYP2D6 nucleic acid comprising rs3892097 (SEQ ID NO: 10), wherein the rs3892097 variable nucleotide is adenine; 11. homozygous for a CYP2D6 nucleic acid comprising rs3892097 (SEQ ID NO: 10), wherein the rs3892097 variable nucleotide is adenine 12. an angiotensin or angiotensinogen polypeptide with a threonine at about position 235 or 268; and/or 13. an angiotensin nucleic acid with rs699 (SEQ ID NO: 14), wherein the rs699 variable nucleotide is cytosine; 14. an angiotensin II receptor (type-I) nucleic acid with rs5186 (SEQ ID NO: 16), wherein the rs5186 variable nucleotide is a cytosine; 15. a renin nucleic acid with rs12750834 (SEQ ID NO:20), wherein the rs12750834 variable position is a cytosine; 16. a Na +  channel (SCNN1A) polypeptide or a Na +  channel (SCNN1A) nucleic acid encoding threonine at position 663; 17. an adducin polypeptide or an adducin nucleic acid encoding tryptophan at position 460; 18. a sodium (Na + ) chloride (Cl \u2212 ) co-transporter (SLC12A3) polypeptide or a SLC12A3 nucleic acid encoding alanine at position 264; 19. a WNK1 nucleic acid with a cytosine detectable by SNP analysis using rs1159744 or rs2107614; And administering the first line drug to the patient according to one of the procedures a)-h):\n a. Administering a beta-blocker drug to the patient as a first line therapy if the sample presents a DNA or peptide sequence of:\n 1. an ADRB1 (\u03b2 1 AR) polypeptide with serine at about position 49; \n 2. an ADRB1 nucleic acid with rs1801252 (SEQ ID NO:2), wherein the rs1801252 variable nucleotide is adenine; \n 3. an ADRB1 (\u03b2 1 AR) polypeptide with arginine at about position 389; \n 4. an ADRB1 nucleic acid with rs1801253 (SEQ ID NO:3), wherein the rs1801253 variable nucleotide is cytosine; \n 5. an ADRB2 (\u03b2 2 AR) polypeptide with glycine at about position 16; \n 6. an ADRB2 nucleic acid with rs1042713 (SEQ ID NO:6), wherein the rs1042713 variable nucleotide is guanine; \n 7. an ADRB2 (\u03b2 2 AR) polypeptide with glutamic acid at about position 27; and/or \n 8. an ADRB2 nucleic acid with rs1042714 (SEQ ID NO:7), wherein the rs1042714 variable nucleotide is guanine; \n \n b. Administering atenolol or carvedilol to the patient as a first line therapy if the sample presents a CYP2D6 polypeptide or a CYP2D6 nucleic acid with a CYP2D6-defective mutation; \n c. Administering atenolol or carvedilol to the patient as a first line therapy if the sample presents DNA or a peptide that is homozygous for a CYP2D6 nucleic acid comprising rs3892097 (SEQ ID NO: 10), wherein the rs3892097 variable nucleotide is adenine such that the patient's CYP2D6 sequence is homozygous A/A at the rs3892097 variable position; \n d. Administering low doses of metoprolol or propranolol to the patient as a first line therapy if the sample presents DNA that is homozygous for a CYP2D6 nucleic acid comprising rs3892097 (SEQ ID NO:10), wherein the rs3892097 variable nucleotide is adenine such that the patient's CYP2D6 sequence is homozygous A/A at the rs3892097 variable position, and wherein the low doses are less than would be administered to a subject who is not A/A homozygous at the rs3892097 variable position; \n e. Administering an ACE inhibitor or an angiotensin receptor blocker to the patient as first line therapy if the sample DNA or polypeptide presents:\n 1. an angiotensin or angiotensinogen polypeptide with a threonine at about position 235 or 268; and/or \n 2. an angiotensin nucleic acid with rs699 (SEQ ID NO: 14), wherein the rs699 variable nucleotide is cytosine; \n \n f. Administering an angiotensin II receptor inhibitor or blocker to the patient as a first line therapy if the sample DNA presents an angiotensin II receptor (type-I) nucleic acid with rs5186 (SEQ ID NO: 16), wherein the rs5186 variable nucleotide is a cytosine; \n g. Administering an angiotensin II receptor inhibitor or blocker to the patient as a first line therapy if the sample DNA comprises a renin nucleic acid with rs12750834 (SEQ ID NO:20), wherein the rs12750834 variable position is a cytosine; \n or \n h. Administering a diuretic to the patient as a first line therapy if the sample DNA or polypeptide presents:\n 1. a Na +  channel (SCNN1A) polypeptide or a Na +  channel (SCNN1A) nucleic acid encoding threonine at position 663; \n 2. an adducin polypeptide or an adducin nucleic acid encoding tryptophan at position 460; \n 3. a sodium (Na + ) chloride (Cl \u2212 ) co-transporter (SLC12A3) polypeptide or a SLC12A3 nucleic acid encoding alanine at position 264; \n 4. a WNK1 nucleic acid with a cytosine detectable by SNP analysis using rs1159744 or rs2107614; or \n 5. any combination thereof.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 88.0
- Lexical Diversity: 1.13636
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15314641', '15037030', '10077870', '15813469', '13799682']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5129288712930068
- 35 USC 102 Novelty (BERT): 0.6048651483548242
- Combined Prediction Score: 0.5221224989991885
- Mean Citation Score: 302.041664
- Max Citation Score: 652.6511
- Similarity Product: 430.3151796323776

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test